Hormone-dependent breast cancer, which is caused by hormonal dysfunction, is partially treated with hormone therapy. Tamoxifen, a drug that blocks the effects of estrogen, is one of the mainstays of this hormone therapy. This is the reference treatment Gold standard as the Anglo-Saxons say. However, about 30% of patients on tamoxifen relapse and die after developing metastases, sometimes several years after treatment. These dramatic consequences have led researchers to redouble their efforts to understand its mechanisms. resistance tamoxifen. The missing link. It will be a protein expressed in tumor cells, the mode of action of which has just been clarified by researchers at the Léon-Bérard Cancer Center in Lyon.
This protein, named PRMT5, has been the subject of increasing interest over the past ten years…
Source: Le Figaro
I am John Sinkler, a professional writer and journalist for Buna Times. I specialize in writing about entertainment-related topics and have been doing so for several years now. My work has been featured on multiple platforms and I’m proud to say that it’s gained recognition from many people in the industry. Aside from working at Buna Times, I also write freelance articles for other publications.